Entero Therapeutics Files 2024 10-K Amendment
Ticker: GRDX · Form: 10-K/A · Filed: Apr 9, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 10-K/A |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financials, pharmaceutical
TL;DR
Entero Therapeutics filed its 2024 10-K amendment, check financials and risks.
AI Summary
Entero Therapeutics, Inc. filed an amendment to its 2024 10-K on April 9, 2025, detailing its financial position as of December 31, 2024. The company, formerly known as First Wave BioPharma, Inc., is in the pharmaceutical preparations industry. Key financial metrics and risk inputs for valuation were disclosed.
Why It Matters
This filing provides updated financial information and disclosures for Entero Therapeutics, Inc., which is crucial for investors and stakeholders to assess the company's performance and risks.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Entero Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition, which are often reflected in 10-K filings.
Key Numbers
- 0.05 — Prime Rate Member (Indicates a specific rate used in financial calculations.)
- 0.143 — Prime Rate Member (Indicates a specific rate used in financial calculations.)
- 2303135 — Measurement Input RiskFreeInterestRateMember (Represents a risk-free interest rate input for valuation as of 2024-12-31.)
- 4754038 — Measurement InputPriceVolatilityMember (Represents price volatility input for valuation as of 2024-12-31.)
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Filer and subject of the report
- First Wave BioPharma, Inc. (company) — Former name of Entero Therapeutics, Inc.
- AzurRx BioPharma, Inc. (company) — Previous former name of Entero Therapeutics, Inc.
- BioPharma d'Azur, Inc. (company) — Earlier former name of Entero Therapeutics, Inc.
- 2024-12-31 (date) — Fiscal year end date for the report
- 20250409 (date) — Filing date of the amendment
FAQ
What is the primary business of Entero Therapeutics, Inc.?
Entero Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When was the 10-K/A amendment filed?
The amendment was filed on April 9, 2025 (20250409).
What was Entero Therapeutics, Inc. previously named?
The company was formerly known as First Wave BioPharma, Inc., AzurRx BioPharma, Inc., and BioPharma d'Azur, Inc.
What is the fiscal year end for this report?
The fiscal year end for this report is December 31, 2024.
What are some of the key valuation inputs disclosed?
The filing discloses inputs such as risk-free interest rates and price volatility for the period ending December 31, 2024.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 9, 2025 regarding Entero Therapeutics, Inc. (GRDX).